CR11631A - Paramyxovirus eficaz como antitumoral - Google Patents

Paramyxovirus eficaz como antitumoral

Info

Publication number
CR11631A
CR11631A CR11631A CR11631A CR11631A CR 11631 A CR11631 A CR 11631A CR 11631 A CR11631 A CR 11631A CR 11631 A CR11631 A CR 11631A CR 11631 A CR11631 A CR 11631A
Authority
CR
Costa Rica
Prior art keywords
paramyxovirus
human
antitumoral
effective
virus
Prior art date
Application number
CR11631A
Other languages
English (en)
Inventor
Beier Rudolf
Puhler Florian
Original Assignee
Bayer Schering Pharma Ag
Grace Procurements Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Grace Procurements Llc filed Critical Bayer Schering Pharma Ag
Publication of CR11631A publication Critical patent/CR11631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen paramyxovirus del grupo APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, virus Mapueray virus Fer-de-Lance, los cuales pueden ser usados para la produccion de un medicamento para el tratamiento de tumores. El virud tienhe la selectividad para matar celulas diferenciadas tumorales humanas pero no para matar celulas diferenciadas normales humanas o en proliferacion normal humanas con la misma dosis.
CR11631A 2008-02-14 2010-08-13 Paramyxovirus eficaz como antitumoral CR11631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08075121 2008-02-14
US2965008P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
CR11631A true CR11631A (es) 2010-10-05

Family

ID=40955326

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11631A CR11631A (es) 2008-02-14 2010-08-13 Paramyxovirus eficaz como antitumoral

Country Status (17)

Country Link
US (1) US20090208495A1 (es)
EP (1) EP2252307A2 (es)
JP (1) JP2011512344A (es)
KR (1) KR20100122482A (es)
CN (1) CN101945660A (es)
AU (1) AU2009214066A1 (es)
BR (1) BRPI0908365A2 (es)
CA (1) CA2715136A1 (es)
CO (1) CO6290694A2 (es)
CR (1) CR11631A (es)
DO (1) DOP2010000251A (es)
EA (1) EA201001266A1 (es)
EC (1) ECSP10010401A (es)
IL (1) IL206860A0 (es)
MX (1) MX2010008942A (es)
WO (1) WO2009101149A2 (es)
ZA (1) ZA201006561B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101745029B1 (ko) * 2009-08-21 2017-06-08 메리얼 인코포레이티드 재조합 조류 파라믹소바이러스 백신 및 이의 제조 및 사용 방법
GB0915515D0 (en) * 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
CA2799076A1 (en) 2010-06-10 2011-12-15 Intervet International B.V. Anti-tumor composition
MY173638A (en) 2012-01-24 2020-02-12 Univ Georgia Parainfluenza virus 5 based vaccines
PL3041490T3 (pl) 2013-09-03 2019-05-31 Medimmune Ltd Kompozycje zawierające atenuowany wirus choroby Newcastle i sposoby ich stosowania w leczeniu neoplazji
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CA3106170A1 (en) * 2018-07-13 2020-01-16 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
CN115089591B (zh) * 2022-05-21 2024-04-12 复旦大学 布立尼布在制备抑制肠道病毒71型嗜神经性病毒药物中的应用
CN116970650B (zh) * 2023-09-22 2023-12-08 深圳华大生命科学研究院 一种包膜蛋白组合、含其的靶向病毒载体及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
CA2383276A1 (en) * 1999-09-24 2001-03-29 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
KR20070085314A (ko) * 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스

Also Published As

Publication number Publication date
EP2252307A2 (en) 2010-11-24
AU2009214066A1 (en) 2009-08-20
WO2009101149A2 (en) 2009-08-20
ZA201006561B (en) 2012-02-29
WO2009101149A3 (en) 2009-11-05
CA2715136A1 (en) 2009-08-20
ECSP10010401A (es) 2010-09-30
CN101945660A (zh) 2011-01-12
CO6290694A2 (es) 2011-06-20
DOP2010000251A (es) 2010-08-31
BRPI0908365A2 (pt) 2015-08-11
US20090208495A1 (en) 2009-08-20
IL206860A0 (en) 2010-12-30
JP2011512344A (ja) 2011-04-21
EA201001266A1 (ru) 2011-04-29
KR20100122482A (ko) 2010-11-22
MX2010008942A (es) 2010-09-07

Similar Documents

Publication Publication Date Title
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
DOP2010000251A (es) Paramyxovirus eficaz como antitumoral
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
EA201591401A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
DOP2015000300A (es) Compuestos de pirimidinodiona contra estados cardíacos
CL2017000290A1 (es) Inhibidores de la proteína kinasa c y métodos de su uso.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
BR112013020041A2 (pt) compostos e métodos para a modulação de quinases, e indicações para os mesmos
EA201590881A1 (ru) Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2
EA201591405A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
MX371275B (es) Composiciones derivadas de la quitosana.
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
MX377118B (es) C. novyi para el tratamiento de tumores solidos en humanos.
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)